BioMaxima S.A. (WSE:BMX)

Market Cap	54.72M
Revenue (ttm)	48.97M
Net Income (ttm)	-454.00K
Shares Out	4.19M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	0.39 (2.93%)
Ex-Dividend Date	n/a

Volume	5,037
Average Volume	5,204
Open	13.30
Previous Close	13.30
Day's Range	13.05 - 13.40
52-Week Range	10.55 - 20.50
Beta	0.35
RSI	54.34
Earnings Date	Apr 30, 2025

About BioMaxima

BioMaxima S.A. manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland. Its primary products include analyzers and diagnostic reagents for testing the biochemical parameters of blood and other body fluids; systems for the determination of drug resistance of microorganisms; quick diagnostic tests for detecting infectious diseases, cancer markers, heart attack markers, and addictive substances and readers; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and r...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1997
• Employees: 115
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: BMX

Financial Performance

In 2023, BioMaxima's revenue was 46.79 million, a decrease of -67.48% compared to the previous year's 143.87 million. Earnings were 586,000, a decrease of -97.97%.